Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation's Testimonials

I am impressed by Bioscience Valuation's very profound, analytical approach to evaluate early discovery projects. Bioscience Valuation substantially supported us in successful partnering negotiations, and it is a continuous pleasure to work with Joachim and his team.

Dr. Torsten Neuefeind, CEO Proteros

Through its 'Corporate Partnership Program', Bioscience Valuation has provided exceptional support in the transformation of our business model. BSV's evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions.

Peter Llewellyn-Davies, CFO/CBO
Medigene AG


Bioscience Valuation's comprehensive assessments of in-licensing candidates provide us with a thorough understanding of the opportunity, both from a scientific and business perspective.

Dr. Philipp R. Hoffmann, Senior Director Business Development & Licensing Europe, Daiichi Sankyo

Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG

I like the insights gained from Bioscience Valuation's thorough assessments that allow me to support my decisions with well-founded, rational arguments.

Dr. Axel Wiest, COO R&D, Merck-Serono

I am impressed with Bioscience Valuation's professional approach that enables us to plan future revenues and capacity utilization much better now.

Dr. Folker Ruchatz, SVP Contract Manufacturing Business, Boehringer Ingelheim Biopharmaceuticals GmbH

Bioscience Valuation's services help me to communicate the value of our business to various stakeholders, including investors.

Dr. Adi Hoess, CEO Affimed

With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.

Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents

Both, breadth and depth of Bioscience Valuation's economic assessments as well as the company's excellent knowledge of healthcare markets are invaluable assets for me in order to reach my goals.

Rick Jackson, Chairman and CEO
Jackson Healthcare